A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

This study looks at two targeted cancer medications, neratinib and palbociclib, to see if they can help stop or shrink tumors in patients whose cancer has certain genetic markers. By blocking the proteins that signal cancer cells to multiply, researchers hope to provide a new, effective treatment option for those whose cancer has returned.

This study is for people with solid tumors (other than breast cancer) that show high levels of a protein called HER2. You must be enrolled in the broader EAY191 study and have your tumor's genetic profile confirmed as a match for this specific group.

Participants will take study medications and undergo regular health monitoring, including blood tests, tissue samples, and imaging scans like X-rays, MRIs, and heart function tests. These tests help doctors keep a close watch on how your body and your tumor are responding to the treatment.

The study is currently recruiting patients at locations in Birmingham and Mobile, Alabama, as well as Anchorage, Alaska. Please speak with your doctor to see if one of these centers is convenient for you.